Dr Brown on the Potential for Pirtobrutinib to Address Treatment Discontinuation in CLL

Jennifer R. Brown, MD, PhD, discusses how pirtobrutinib may address BTK inhibitor discontinuation in chronic lymphocytic leukemia.

Related Keywords

,Jenniferr Brown ,Chronic Lymphocytic Leukemia Center ,Dana Farber Cancer Institute ,Harvard Medical School ,Margaret Collette Professor ,Hematologic Oncology ,Cll ,Dbtk ,Pirtobrutinib ,Ash Annual Meeting ,Genomics ,Chronic Lymphocytic Leukemia ,Jennifer Brown ,D ,Phd ,